Preparing of Cyclodextrin Polymeric Nanoparticles for Enhancing Drug Bioavailability (RSPT2.3)

Abstract

Rosuvastatin calcium is one of a statin medication, used to prevent cardiovascular disease in those at high risk and treat abnormal lipids. It is a poorly soluble drug with oral bioavailability 20% due to extensive first pass effect. The study aimed to formulate cyclo-dextrin loaded polyrotaxane nanoparticles loaded with Rosuvastatin Calcium to improve its solubility, efficacy and reduce side effects. The effects of polymers (PVP), cyclodextrin concentrations or their combinations at different polymers ratios on the drug solubility dissolution rate was studied. The Experimental studies: Polyrotaxane was prepared by dissolving drug, PVP and

cyclodextrane all together. The mixture was cooled for 24 hour to allow precipitation of drug- polyrotaxane powder, then dried at at 40 oC for 24 hours. The dried powdered was weighted. The drug

content of polyrotaxane was determined. 0.05 g of the prepared polyrotaxane was dissolved in 10 ml methanol, to guarantee complete drug solubility. The drug concentration was measured spectrophotometrically at wavelength 243nm. The dissolution test used to compare between the poorly soluble rosuvastatin drug and polyrotaxane. Differential scanning calorimetry test used to concern with the measurement of energy acquired or emitted by a sample of matter when it is heated or cooled. It also provides information about endothermic and exothermic processes. X- Ray powder diffraction is a technique that utilizes x- ray scattering pointed on crystals of powder to give identity and information about the crystalline structure. The Results: The powder weight was 2.8gm presents 22.85 % yield. Five mg of polyrotaxane contains 3.575 mg pure drug (71.5% drug loading and 1%.encapsulation efficiency. Polyrotaxane complex enhance both drug solubility and dissolution.